Limits...
Prognostic value of Ezrin in solid tumors: a meta-analysis of the literature.

Han K, Qi W, Gan Z, Shen Z, Yao Y, Min D - PLoS ONE (2013)

Bottom Line: Several databases were searched, including Pubmed, Embase and Cochrane databases.The endpoints were overall survival (OS), progression-free survival (PFS).So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Shanghai Sixth People's Hospital East Campus, Shanghai Jiao Tong University, Shanghai, China.

ABSTRACT

Purpose: Ezrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial.

Methods: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.

Results: Twenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60-2.39; P<0.001] in all eligible studies and progress free survival (PFS): (2.30 95% CI 1.0-3.61; P = 0.001). Similar results were also observed in subgroup analysis, according to tumor types, regions, patients' number and publication year.

Conclusions: Our findings suggested that Ezrin protein expression might be a factor for a poor prognosis in patients with solid tumor. So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

Show MeSH

Related in: MedlinePlus

Ezrin expression and PFS.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3716773&req=5

pone-0068527-g003: Ezrin expression and PFS.

Mentions: The results of the meta-analysis were shown in Fig. 2 and Fig. 3. The combined HR for 22 studies evaluating Ezrin overexpression on OS was 1.95, (95% CI: 1.60–2.39), suggesting that Ezrin overexpression was an indicator of poor prognosis for solid tumor. Significant heterogeneity was observed among the studies. (Q = 55.4, I2 = 62.1%, P<0.001). When grouped according to geographic settings of individual studies, the combined HRs of Asian studies and non-Asian studies were 2.006 (95% CI: 1.483–2.529) and 1.498 (95%CI: 1.260–1.735) respectively. Subgroupanalysiscouldhelpusdiscoverpotentialinformation of what the clinicians were interested in. Therefore, we studied some factors that might be related with survival. The studies from the tumor types, regions, patients' number and publication year were considered as the subgroup analysis factors. Finally, all subgroup analyses favored Ezrin overexpression be associated with poor OS (Table 2). 7 studies evaluating Ezrin overexpression on PFS was 2.30, (95% CI: 1.00–3.61), indicate that Ezrin overexpression was an indicator of poor prognosis for solid tumor using random effect model(Q = 96.05, I2 = 92.1%, P<0.001).


Prognostic value of Ezrin in solid tumors: a meta-analysis of the literature.

Han K, Qi W, Gan Z, Shen Z, Yao Y, Min D - PLoS ONE (2013)

Ezrin expression and PFS.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3716773&req=5

pone-0068527-g003: Ezrin expression and PFS.
Mentions: The results of the meta-analysis were shown in Fig. 2 and Fig. 3. The combined HR for 22 studies evaluating Ezrin overexpression on OS was 1.95, (95% CI: 1.60–2.39), suggesting that Ezrin overexpression was an indicator of poor prognosis for solid tumor. Significant heterogeneity was observed among the studies. (Q = 55.4, I2 = 62.1%, P<0.001). When grouped according to geographic settings of individual studies, the combined HRs of Asian studies and non-Asian studies were 2.006 (95% CI: 1.483–2.529) and 1.498 (95%CI: 1.260–1.735) respectively. Subgroupanalysiscouldhelpusdiscoverpotentialinformation of what the clinicians were interested in. Therefore, we studied some factors that might be related with survival. The studies from the tumor types, regions, patients' number and publication year were considered as the subgroup analysis factors. Finally, all subgroup analyses favored Ezrin overexpression be associated with poor OS (Table 2). 7 studies evaluating Ezrin overexpression on PFS was 2.30, (95% CI: 1.00–3.61), indicate that Ezrin overexpression was an indicator of poor prognosis for solid tumor using random effect model(Q = 96.05, I2 = 92.1%, P<0.001).

Bottom Line: Several databases were searched, including Pubmed, Embase and Cochrane databases.The endpoints were overall survival (OS), progression-free survival (PFS).So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Shanghai Sixth People's Hospital East Campus, Shanghai Jiao Tong University, Shanghai, China.

ABSTRACT

Purpose: Ezrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial.

Methods: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.

Results: Twenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60-2.39; P<0.001] in all eligible studies and progress free survival (PFS): (2.30 95% CI 1.0-3.61; P = 0.001). Similar results were also observed in subgroup analysis, according to tumor types, regions, patients' number and publication year.

Conclusions: Our findings suggested that Ezrin protein expression might be a factor for a poor prognosis in patients with solid tumor. So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

Show MeSH
Related in: MedlinePlus